Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that its Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion, scheduled for June 4, 2026, at 2:35 p.m. EDT, will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. The full press release is available at https://ibn.fm/1QdP7.
This engagement is significant as it provides Helus Pharma with a platform to discuss its lead programs with the investment community. The company is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD), which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder (GAD). Helus Pharma’s pipeline also includes an extensive research portfolio of investigational NSAs designed to activate serotonin pathways believed to promote neuroplasticity.
The company’s focus on NSAs aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma intends to improve the treatment landscape by introducing NSAs that provide durable improvements in mental health. The Breakthrough Therapy Designation for HLP003 underscores the potential of this therapy to offer significant advantages over existing treatments for MDD.
Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. The company’s newsroom is available at https://ibn.fm/HELP.
